Adverum Biotechnologies 11/4/2024 Earnings Report $4.33 +0.04 (+0.93%) As of 01/17/2025 04:00 PM Eastern Earnings HistoryForecast Adverum Biotechnologies EPS ResultsActual EPS-$1.30Consensus EPS -$1.20Beat/MissMissed by -$0.10One Year Ago EPSN/AAdverum Biotechnologies Revenue ResultsActual Revenue$1.00 millionExpected Revenue$0.50 millionBeat/MissBeat by +$500.00 thousandYoY Revenue GrowthN/AAdverum Biotechnologies Announcement DetailsQuarterDate11/4/2024TimeAfter Market ClosesConference Call ResourcesADVM Earnings History Adverum Biotechnologies Earnings HeadlinesAdverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 6, 2024 | globenewswire.comAdverum Biotechnologies price target lowered to $16 from $20 at MizuhoNovember 23, 2024 | markets.businessinsider.comKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware of… yet have the potential to deliver colossal returns over the next four years. I’m not talking about Tesla, Palantir, or anything else you’ve heard parroted by the mainstream financial press. No. These are Trump’s Secret Stocks. January 20, 2025 | Porter & Company (Ad)Adverum Biotechnologies, Inc.: Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)November 22, 2024 | finanznachrichten.deTruist Financial Sticks to Their Buy Rating for Adverum Biotechnologies (ADVM)November 20, 2024 | markets.businessinsider.comAdverum Biotechnologies reports results of two trials of Ixo-vec in AMDNovember 18, 2024 | markets.businessinsider.comSee More Adverum Biotechnologies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Adverum Biotechnologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adverum Biotechnologies and other key companies, straight to your email. Email Address About Adverum BiotechnologiesAdverum Biotechnologies (NASDAQ:ADVM), a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.View Adverum Biotechnologies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings Interactive Brokers Group (1/21/2025)Netflix (1/21/2025)HDFC Bank (1/21/2025)Charles Schwab (1/21/2025)Prologis (1/21/2025)3M (1/21/2025)Capital One Financial (1/21/2025)ICICI Bank (1/22/2025)Kinder Morgan (1/22/2025)Amphenol (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
